Skip to main content

Evidence-Based Supplement Research

Evidence-Based Supplement Research

Magnesium and Reduced Aspartate Aminotransferase Level

Doses used in studies

mg/day: 150 (median 150, IQR 150–150) — 1 study

Time to effect

Median: 3.7 months · IQR 3.7 months–3.7 months · Range 3.7 months–3.7 months — Reported in 1 of 1 study

1 of 1 paper

Hepatoprotective effect of combination of L-carnitine and magnesium-hydroxide in nonalcoholic fatty liver disease patients: a double-blinded randomized controlled pilot study.
- 2022-10-01
- RCT
- European review for medical and pharmacological sciences 26(20)
- - R Hazzan
  - N Abu Ahmad
  - W Slim
  - E Mazen
  - Z Neeman
- PubMed: 36314323
- DOI: 10.26355/eurrev_202210_30023
6 Insights on
- Reduced Aspartate Aminotransferase Level
- High evidence
- Clinical
AST and ALT levels of the treatment group decreased by 25% (p=0.9) and 20% (p=0.1) respectively, compared to AST and ALT levels at baseline.
Effect
Neutral
Effect size
Small
Significant
No
Dose
150 mg/day